Tuberculosis following PD-1 blockade for cancer immunotherapy.
Aged, 80 and over
Animals
Antibodies, Monoclonal, Humanized
/ therapeutic use
Carcinoma, Merkel Cell
/ drug therapy
Fatal Outcome
Granuloma
/ pathology
Humans
Immunotherapy
/ adverse effects
Male
Middle Aged
Mycobacterium tuberculosis
/ immunology
Nasopharyngeal Neoplasms
/ drug therapy
Neoplasms
/ immunology
Nivolumab
/ therapeutic use
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Th1 Cells
/ immunology
Tuberculosis
/ etiology
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
16 01 2019
16 01 2019
Historique:
received:
09
03
2018
revised:
02
10
2018
accepted:
06
12
2018
entrez:
18
1
2019
pubmed:
18
1
2019
medline:
23
2
2020
Statut:
ppublish
Résumé
Because of the well-established therapeutic benefit of boosting antitumor responses through blockade of the T cell inhibitory receptor PD-1, it has been proposed that PD-1 blockade could also be useful in infectious disease settings, including
Identifiants
pubmed: 30651320
pii: 11/475/eaat2702
doi: 10.1126/scitranslmed.aat2702
pmc: PMC7372940
mid: NIHMS1602940
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Programmed Cell Death 1 Receptor
0
Nivolumab
31YO63LBSN
pembrolizumab
DPT0O3T46P
Types de publication
Case Reports
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Organisme : NCI NIH HHS
ID : K24 CA139052
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA154967
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186717
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA154967
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA162522
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI074492
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA138292
Pays : United States
Informations de copyright
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Références
Int J Infect Dis. 2017 Mar;56:221-228
pubmed: 28163164
Clin Microbiol Infect. 2018 Mar;24(3):216-218
pubmed: 29269089
J Immunol. 2014 Apr 1;192(7):2965-9
pubmed: 24591367
Infect Immun. 2009 Oct;77(10):4621-30
pubmed: 19667047
J Exp Med. 2010 Aug 2;207(8):1609-16
pubmed: 20624887
Int Immunol. 2010 Dec;22(12):915-25
pubmed: 21047981
J Infect Chemother. 2019 Jan;25(1):54-58
pubmed: 30055859
PLoS One. 2016 Jul 01;11(7):e0158262
pubmed: 27367521
BMC Med. 2016 Jun 15;14:89
pubmed: 27301245
PLoS Pathog. 2016 Mar 11;12(3):e1005490
pubmed: 26967901
PLoS One. 2011 May 12;6(5):e19864
pubmed: 21589883
J Thorac Oncol. 2016 Dec;11(12):2238-2240
pubmed: 27423391
Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
Nat Rev Immunol. 2015 Apr;15(4):255-63
pubmed: 25765201
Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19408-13
pubmed: 20962277
Immunity. 2013 Jun 27;38(6):1261-70
pubmed: 23791647
Mucosal Immunol. 2018 Mar;11(2):462-473
pubmed: 28745326
Lancet Infect Dis. 2007 May;7(5):328-37
pubmed: 17448936
Acta Oncol. 2016;55(4):519-20
pubmed: 26754959
Nat Rev Immunol. 2018 Sep;18(9):591-596
pubmed: 29872140
Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13402-7
pubmed: 20624978
J Clin Oncol. 2018 May 10;36(14):1412-1418
pubmed: 29584545
N Engl J Med. 2016 Jun 30;374(26):2542-52
pubmed: 27093365
PLoS Pathog. 2016 May 31;12(5):e1005667
pubmed: 27244558
Nat Rev Immunol. 2018 Feb;18(2):91-104
pubmed: 28990586
J Thorac Oncol. 2017 Aug;12(8):e111-e114
pubmed: 28748816
Clin Vaccine Immunol. 2010 Oct;17(10):1539-47
pubmed: 20719988
J Immunol. 2011 Feb 1;186(3):1598-607
pubmed: 21172867
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Infect Genet Evol. 2012 Jun;12(4):782-8
pubmed: 22044522
Front Immunol. 2018 Aug 31;9:1995
pubmed: 30233588